Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
ARKGvsLFSCETF Comparison
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. F/m Emerald Life Sciences Innovation ETF (LFSC) is part of the Life Sciences segment. ARKG's top 3 sector exposures are Health Care and Information Technology. In contrast, LFSC's top sector exposures are Health Care and Sovereign. ARKG is less expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.79% for LFSC. ARKG is down -5.11% year-to-date (YTD) with -$10M in YTD flows. LFSC performs worse with -8.11% YTD performance, and +$5M in YTD flows. Run a side-by-side ETF comparison of ARKG and LFSC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
ARKG vs LFSC performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG LFSC | -3.62%-5.63% | -10.23%-12.79% | -5.11%-8.11% | +23.23%+50.10% | -2.84%n/a | -70.08%n/a |
| Flows | ARKG LFSC | -$50M+$6M | -$85M+$6M | -$10M+$5M | -$210M+$16M | -$627M- | -$2.79B- |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG LFSC | +39.15%+22.79% | +44.62%+28.72% | +42.26%n/a | +45.19%n/a |
| Max drawdown | ARKG LFSC | -19.50%-14.28% | -23.94%-19.03% | -51.98%n/a | -80.33%n/a |
| Max drawdown duration | ARKG LFSC | 48d78d | 77d70d | 966dn/a | 1822dn/a |
ARKG | LFSC | |
Last sale 3/13/2026 at 1:30 PM | $26.36 | $33.61 |
| Previous close 03/12/2026 | $26.17 | $33.82 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
ARKG | LFSC | |
|---|---|---|
| Last price | $26.36 | $33.61 |
| 1D performance | +0.73% | -0.62% |
| AuM | $1.11 B | $90.06 M |
| E/R | 0.75% | 0.79% |
ARKG | LFSC | |
|---|---|---|
| Management strategy | Active | Active |
| Provider | Ark Investment | Emerald Group |
| Benchmark | - | - |
| N° of holdings | 30 | 34 |
| Asset class | - | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | October 31, 2024 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the ARKG and LFSC ETFs performed in 2026?
As of March 11, 2026, ARKG is down -5.11% year-to-date (YTD), while LFSC has lost -8.11%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or LFSC?
Year-to-date, the ARKG ETF saw -$10M in flows, compared to +$5M for LFSC.
Which ETF is more volatile: ARKG or LFSC?
Over the past year, ARKG had a volatility of 44.62%, while LFSC experienced 28.72%.
Which ETF is bigger: ARKG or LFSC?
As of March 11, 2026, ARKG holds $1.11 B in assets under management (AUM), while LFSC manages $90.06 M.
What sectors do the ARKG and LFSC ETFs invest in?
ARKG leans toward sectors like Health Care. Meanwhile, LFSC focuses on Health Care.
What are the top holdings of the ARKG ETF and LFSC ETF?
ARKG top holdings include CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC. LFSC holds in its top three: COGENT BIOSCIENCES, LIVANOVA and GUARDANT HEALTH INC.
Which ETF is more diversified: ARKG or LFSC?
ARKG holds 30 securities with 63.79% of its assets in the top 15. LFSC has 42 securities and a top 15 weight of 68.94%.
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
